Here's Why Grail Stock Surged 55% This Week
The company received a favorable vote from the FDA this week, which could open up significant adoption of its multi-cancer early detection test, Galleri.
Overview
Multi-cancer early detection (MCED) test company Grail (NASDAQ: GRAL) stock surged 55% through Friday morning after the Food and Drug Administration (FDA) voted favorably on its Galleri MCED test. The vote opens the pathway for the FDA to grant premarket approval to Galleri and, in turn, for increased adoption by medical bodies and insurers.
The Molecular and Clinical Genetics Devices Panel of the FDA's Medical Devices Advisory Committee voted unanimously on Galleri's safety, seven to two, that Galleri's benefits outweigh its risks, and, in the most eagerly awaited vote, Galleri received a six-to-four vote in favor of its effectiveness.
Details
The vote increases the likelihood of pre-market approval and may open conversations with medical insurers that might not consider Galleri without FDA approval. The close efficacy vote indicates the key issue for Grail. The Galleri test missed its primary endpoint: a statistically meaningful reduction in late-stage (Stage III and Stage IV) cancer detection in a three-year, 142,250-person trial with England's National Health Service.
Source
Originally published at www.fool.com.
Related Articles
- After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring
- Warren Buffett's Successor, Greg Abel, Has 55% of Berkshire Hathaway's $360 Billion Portfolio Invested in 4 Standout Stocks
- Meta’s Muse AI Downloads Are Soaring. Is It Time to Buy This Bargain AI Stock?